Open AccessValidation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for Mycobacterium tuberculosis
Author(s) -
Rajesh Mondal,
Gomathi Sivaramakrishnan,
Balaji Subramanyam,
MichelPrem Kumar,
Radhika Golla,
Srikanth Tripathy
Publication year - 2019
Publication title -
international journal of mycobacteriology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 20
eISSN - 2212-554X
pISSN - 2212-5531
DOI - 10.4103/ijmy.ijmy_151_19
Subject(s) - bedaquiline , repeatability , reproducibility , tuberculosis , mycobacterium tuberculosis , medicine , microbiology and biotechnology , chromatography , chemistry , biology , pathology
Bedaquiline (BDQ) is a new antituberculosis (TB) drug effectively used for the treatment of multidrug-resistant and extensively drug-resistant TB. However, the reports on drug-susceptibility testing (DST) for BDQ are scarce. The study aimed to validate and standardize BDQ DST by BACTEC MGIT 960 system for Mycobacterium tuberculosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom